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Early complications and long-term outcome after
open surgical treatment of popliteal artery
aneurysms: Is exclusion with saphenous vein
bypass still the gold standard?
Ying Huang, MD, PhD, Peter Gloviczki, MD, Audra A. Noel, MD, Timothy M. Sullivan, MD,
Manju Kalra, MD, Rachel E. Gullerud, BS, Tanya L. Hoskin, MS, and Thomas C. Bower, MD,
Rochester, Minn
Background: Popliteal artery aneurysms (PAAs) are rare, but thromboembolic complications may result in limb loss. To
define complications and outcomes after open surgical repairs, we reviewed our experience.
Methods: Clinical data of patients with PAA seen between 1985 and 2004 at Mayo Clinic, Rochester, Minnesota, were
reviewed and outcomes in 289 patients with open revascularization were analyzed. Kaplan-Meier method with log-rank
tests, 2, and Wilcoxon rank sum tests were used for analysis.
Results:A total of 358 PAAs were treated in 289 patients, consisting of 281 (97%)men and eight (3%) women. There were
133 (46%) unilateral and 156 (54%) bilateral PAAs with a mean diameter of 2.9 cm (range, 1.5 to 9 cm). Abdominal
aortic aneurysm (AAA) was more frequent with bilateral than unilateral PAAs (65% [101/156] vs 42% [56/133] P 
.001). There were 144 (40%) asymptomatic limbs (group 1), 140 (39%) had chronic symptoms (group 2), and 74 (21%)
had acute ischemia (group 3). Great saphenous vein (GSV) was used in 242 limbs (68%), polytetrafluoroethylene (PTFE)
in 94 (26%), and other types of graft in 22 (6%). Early mortality was 1% (3/358), all in group 3 (4% [3/74]). Six of seven
patients with perioperative myocardial infarctions belonged to group 3 (8%). The 30-day graft thrombosis rate was 4%,
with 1% in group 1 (1/144), 4% in group 2 (5/140), and 9% in group 3 (7/74). All six early amputations (8%) were in
group 3, five with failed bypass (4 PTFE, 1 GSV). Mean follow-up was 4.2 years (range, 1 month to 20.7 years). The
5-year primary and secondary patency rates were 76% and 87%, respectively, higher with GSVs (85% and 94%) than PTFE
(50% and 63%, P< .05). Seven recurrent PAAs (2%) required reintervention. The 5-year freedom from reintervention was
100% after endoaneurysmorrhaphy vs 97% after ligations (P  .03). Five-year limb salvage rate was 97% (85% in group
3). There was no limb loss in group 1 and none in group 2 with GSV. In group 3, preoperative thrombolysis reduced the
amputation rate in class II patients with marginally threatened limbs (96% vs 69%, P  .02).
Conclusion: Acute presentation of PAA continues to carry high mortality and cardiac morbidity; although preoperative
thrombolysis appears to improve results, the 8% early and 15% late amputation rates remain ominous. Early elective repair
is recommended because these patients had no surgical mortality, a low rate of complications, and asymptomatic patients
had no limb loss at 5 years. GSV and endoaneurysmorrhaphy continues to be the gold standard for open repair of PAA.
(J Vasc Surg 2007;45:706-15.)Popliteal artery aneurysms (PAAs) are rare, with a prev-
alence of 0.01% reported in hospitalized patients.1 These
aneurysms account for up to 70% of all peripheral arterial
aneurysms.1 The most frequent and severe complication is
thromboembolism, with subsequent acute limb ischemia
and major amputation rate of up to 30% in surgical se-
ries.2-16 The disease is bilateral in approximately half of the
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706cases, and one in two patients with PAAs will also harbor an
abdominal aortic aneurysm (AAA).
Open surgical treatment includes in situ arterial re-
placement or a bypass using autologous or prosthetic graft.
To decrease late recurrence of the aneurysm, endoaneu-
rysmorrhaphy has been preferred over simple ligation of the
artery proximal and distal to the aneurysm.17 Thrombolysis
has been used to improve outflow in patients with acute
presentation.9,18,19
Several reports, including one prospective randomized
study, have advocated endovascular treatment of PAAs over
open surgical management.20-23 To provide standards for
comparison, the aim of our study was to define contempo-
rary complications and long-term outcomes of patients
treated with conventional open surgical techniques.
METHODS
The clinical data of patients with the diagnosis of PAA
seen at Mayo Clinic, Rochester, Minnesota, between 1985
and 2004, were reviewed, and outcomes in 289 patients
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analyzed. The study was approved by theMayo Foundation
Institutional Review Board. Clinical categories for both
acute and chronic limb ischemia and criteria for primary
and secondary patency were defined as recommended by
Rutherford et al.24 Cardiac, pulmonary, and renal risk
factors were documented using criteria of the Department
of Veterans Affairs National Surgical Quality Improvement
Program (NSQIP).25 PAA was defined as focal dilation of
the popliteal artery by 50% over the expected normal
diameter (0.9  0.2 cm), as measured with ultrasonogra-
phy,26 or a diameter 1.5 cm when measured intraopera-
tively.27
Patients were divided into three groups: asymptomatic
limbs (group 1), symptoms of chronic limb ischemia
(group 2), and limbs with acute limb ischemia (group 3).
Local compression was defined if symptoms of numbness,
tingling, pain, or feeling of fullness in the popliteal fossa or
signs of edema or popliteal vein thrombosis were docu-
mented in the chart. Indications for operation included
acute limb ischemia with a salvageable limb, PAAs with
compressive symptoms or disabling claudication, asymp-
tomatic PAA with aneurysm 2 cm in size, or those with
mural thrombus or evidence of previous thromboembo-
lism.8
Operative technique. Most revascularizations were
performed through a median approach. If the aneurysm
involved the proximal popliteal artery, inflow for the bypass
was the superficial femoral or common femoral artery. The
distal popliteal artery, one of the tibials, or the peroneal
artery was the site of the distal anastomosis. Proximal and
distal ligation was usually used for small aneurysms, and
endoaneurysmorrhaphy was performed at the discretion of
the surgeon, usually in patients with a large aneurysm (2
cm) or if large genicular arteries were noted on preoperative
imaging.
The aneurysm was opened, thrombus evacuated, and
the lumen oversewn, usually without transection of the
medial head of the gastrocnemius muscle. A thigh tourni-
quet facilitated endoaneurysmorrhaphy in a bloodless field.
If the posterior approach was used, the aneurysm was
opened and feeding arterial branches were ligated or over-
sewn. Reconstruction was performed with autologous or
prosthetic bypass, or interposition graft. Prosthetic graft
was used at the discretion of the surgeon, usually only if a
suitable autologous vein was not available.
Indications for thrombolysis included patients with
acute limb ischemia in a viable extremity. Decisions to
proceed with thrombolysis were made at the discretion of
the interventionists. In group 3, 34 patients had intra-
arterial thrombolysis (preoperative, 24; intraoperative, 14;
both, 4). Of the 24 patients who had preoperative lytic
treatment, 23 presented with threatened limb ischemia (class
II) and one with irreversible limb ischemia (class III). Uroki-
nase was used at a dosage of 1000 U/min to 4000U/min in
16 patients. Tissue plasminogen activator (t-PA) was given at
0.5 mg/h in eight patients. Mean duration of thrombolysis
was 19  13 hours. For intraoperative thrombolysis, sevenpatients had urokinase (60,000 U to 250,000 U) and three
had t-PA (0.5 mg to 1 mg). Activated partial thromboplas-
tin time and fibrinogen were monitored during thrombol-
ysis.
Information on concomitant aneurysms was obtained
from reports of imaging studies and from history of previ-
ous aneurysm repairs. Of 289 patients, 271 underwent
imaging of the contralateral popliteal fossa or had repair of
a contralateral popliteal aneurysm previously; 274 patients
underwent imaging of the aortoiliac vessels or had repair of
an aortoiliac aneurysm previously. Follow-up information
was obtained from the medical records and mailed ques-
tionnaires. Mailing was used to establish survival and limb
loss. Patients were advised to return every 6 months, and
patency rates were based on the last imaging studies.
During the time interval of this study, an additional 10
PAAs were treated by primary major amputation (n  2),
ligation alone (n  2), endoaneurysmorrhaphy alone (n 
4), lumbar sympathectomy (n 1), and stent graft (n 1).
One of these patients presented with aneurysm rupture.
These patients were excluded from our analysis.
Statistical analysis. Descriptive statistics, including
means, standard deviations, ranges, and proportions were
calculated as appropriate. Rates of patency, reintervention
for recurrent PAA, amputation per limb, and survival were
estimated using the Kaplan-Meier method with log-rank
tests to compare groups. Multivariate analyses were per-
formed using Cox proportional hazards regression. Length
of stay in the hospital and the intensive care unit (ICU)
were compared between groups using Wilcoxon rank sum
tests. The 2 test or Fisher exact test, as appropriate, were
used to assess associations with binary outcomes such as
early morbidity. Values of P  .05 were considered statis-
tically significant for all analyses. Analyses were performed
using SAS 9 software (SAS Institute, Inc, Cary, NC).
RESULTS
Demographic data. Between 1985 and 2004, 494
patients were diagnosed with 651 PAAs at Mayo Clinic.
Open surgical revascularizations were done in 289 patients
for 358 PAAs; they were the subjects of this study (Table I).
Of these, 281 men (97%) and eight women (3%) had 133
(46%) unilateral and 156 (54%) bilateral PAAs. At least one
remote aneurysm was present in 192 patients (66%), more
frequently in those with bilateral vs unilateral PAAs (79%
[123/156] vs 52% [69/133], P  .001). Of the patients
who had both femoral and PAA, 74% also had AAA. AAA
was present in 157 patients (54%), more frequently in
patients with bilateral vs unilateral PAAs (65% [101/156]
vs 42% [56/133], P  .001; Fig 1).
Clinical characteristics. Ultrasound imaging con-
firmed the diagnosis in 311 limbs (87%), 341 limbs (95%)
were studied with contrast arteriography, 12 (3%) had
computed tomography (CT) scan or CT angiography
(CTA), and 12 (3%) hadmagnetic resonance (MR) angiog-
raphy (MRA). The diameter of the aneurysm was measured
with ultrasound in 309 limbs, CT scan in one, and MRA in
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intraoperativemeasurements were used when documented.
Thrombus was present in 337 PAAs (94%), and 95
(27%) had a completely thrombosed popliteal artery. In
group 3, 66% (49/74) had a thrombosed popliteal artery.
Runoff was assessed in 349 (97%) limbs: 341 (98%) were
assessed with contrast arteriography and eight (2%) with
Table I. Demographic data and risk factors of 289
patients with 358 popliteal artery aneurysms
Data No (%)
Patients 289 (100)
Male 281 (97)
Female 8 (3)
Age, mean y (range) 70 (17-88)
Risk factors*
Cardiovascular 128 (44)
Pulmonary 41 (14)
Renal 3 (1)
Hypertension 192 (66)
Diabetes mellitus 46 (16)
Current smokers 81 (28)
*As defined by Department of Veterans Affairs National Surgical Quality
Improvement Program.25
Fig 1. Prevalence of concomitant aneurysms in 299 patients with
popliteal artery aneurysms.CTA arteriography. A total of 144 PAAs (40%) wereasymptomatic (group 1), 140 (39%) had chronic limb
ischemia (group 2), and 74 (21%) had acute limb ischemia
(group 3; Table II). Mean aneurysm diameter was 2.9 
1.1 cm (range, 1.5 to 9 cm). Current or previous deep vein
thrombosis (DVT) was present in 20 limbs (6%), 36 (10 %)
had symptoms of local compression by the aneurysm, 28
(8%) limbs had blue toe syndrome, and no aneurysms
ruptured.
Intraoperative data. All 358 PAAs were repaired with
bypass or interposition graft: 337 (94%) were performed
through a medial approach, and 21 (6%) through a poste-
rior approach (Table III). Pathologic studies of 236 PAAs
showed degenerative atherosclerosis in 232 aneurysms
(98.3%), fibromuscular dysplasia in three (1.3%), and
thromboangiitis obliterans in one (0.4%).
Early outcomes
Mortality. The 30-day overall mortality was 1% (3/
358). All deaths occurred in group 3, for an early mortality
of 4% (3/74). The causes of death were myocardial infarc-
tion, cardiac arrhythmia, and adult respiratory distress syn-
drome, in one patient each. Two of the three deaths were
preceded by major amputation.
Limb loss. The 30-day amputation rate was 2% (6/
358). All amputations, one below the knee and five above
the knee, were performed in group 3 patients (8% [6/74]).
One patient had a patent graft. Five of the group 3 ampu-
tations were performed after failed bypass grafts consisting
of polytetrafluoroethylene (PTFE) in four, and great saphe-
nous vein (GSV) in one.
Morbidity and graft failure. Systemic complications
Table II. Clinical data of 358 limbs with popliteal artery
aneurysms
Data N limbs with PAA (%)
Clinical class
Group 1 (asymptomatic) 144 (40)
Group 2 (chronic limb ischemia)* 140 (39)
1 Mild claudication 32 (23)
2 Moderate claudication 37 (26)
3 Severe claudication 21 (15)
4 Ischemic rest pain 29 (21)
5 Minor tissue loss 21 (15)
6 Major tissue loss 0 (0)
Group 3 (acute limb ischemia)* 74 (21)
I Viable 28 (38)
IIa Marginally threatened 31 (42)
IIb Immediately threatened 12 (16)
III Irreversible 3 (4)
Total 358
Mean (range)
Size of aneurysm (cm) 2.9  1.1 (1.5-9)
Group 1 2.6  0.8 (1.5-5)
Group 2 3.0  1.3 (1.5-9)†
Group 3 2.9  0.9 (1.5-5)†
*Rutherford, et al.24
†P  .05 compared with group 1.occurred in 27 patients (8%), most frequently in group 3
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myocardial infarctions (group 1, 0%; group 2, 1% [1/140];
group 3, 8% [6/74]; Table IV). By 30 days, 13 grafts (4%) had
thrombosed (group 1, 1 [1%]; group 2, 5 [4%]; group 3, 7
[9%]; Table IV).
Hospital length of stay. Median ICU and hospital
length of stays were 1 and 6 days in group 1, and 1 and 8
days in group 2, respectively, both of which were shorter
Table III. Surgical data of 358 operations for popliteal ar
Surgical data Group 1
Type of surgery
Bypass 140 (97)
Endoaneurysmorrhaphy 50 (36)
Ligation 87 (62)
Excision 3 (2)
Bypass alone —
In situ interposition 4 (3)
Conduit
Autogenous graft 108 (75)
GSV 97
Non-reversed 36 (37)
Reversed 61 (63)
SSV 5
Non-reversed 1
Reversed 4
Arm vein 4
Spliced vein 2
Prosthetic graft 36 (25)
PTFE 34 (94)
Dacron 2 (6)
PTFE-vein sequential —
Total grafts 144
Group 1, Asymptomatic; Group 2, patients with chronic limb ischemia; Gr
saphenous vein; PTFE, polytetrafluoroethylene.
Table IV. Early complications
Complication
N
Group 1
(n  144)
Systemic morbidity 3 (2)
Cardiac 1 (1)
Cardiac arrest 1 (1)
Myocardial infarction 0
Arrhythmia 0
Pulmonary 0
Acute renal failure 0
Deep vein thrombosis 2 (1)
Wound 7 (5)
Wound infection 4 (3)
Wound dehiscence 1 (1)
Hematoma 3 (2)
Lymph leak 0
Graft failure 1 (1)
Group 1, asymptomatic; Group 2, patients with chronic symptoms; Group 3
*P  .05 compared with group 1.
†P  .05 compared with group 2.than the respective 2 and 12 days in group 3 (P  .0001).Thrombolysis. The 30-day primary patency rate was
94%  4% for 34 patients with thrombolysis vs 87%  5%
for 39 patients without thrombolysis (P  NS). The limb
salvage rate was 91%  5% vs 92%  4% (P  NS). The
primary patency and limb salvage rates were better in limbs
with class II ischemia (threatened limb ischemia) with preop-
erative thrombolysis thanwithout thrombolysis (96% 4% vs
80%  9%, P  .02; 96%  4% vs 85%  8%, P  .02,
aneurysms
esentation, n (%)
TotalGroup 2 Group 3
134 (99) 74 (100) 348 (97)
39 (29) 26 (35) 115 (33)
86 (64) 43 (58) 216 (62)
7 (5) 5 (7) 15 (4)
2 (2) — 2 (1)
6 (1) — 10 (3)
101 (72) 50 (68) 259 (72)
95 50 242
39 (41) 18 (36) 93 (38)
56 (59) 32 (64) 149 (62)
2 — 7 (2)
1 — 2 (40)
1 — 5 (60)
2 — 6 (2)
2 — 4 (1)
39 (28) 22 (30) 97 (27)
38 (97) 22 (100) 94 (26)
1 (3) — 3 (1)
— 2 2 (1)
140 74 358
patients with acute limb ischemia; GSV, great saphenous vein; SSV, short
er of patients (%)
Total
(n  358)
Group 2
(n  140)
Group 3
(n  74)
10 (7)* 14 (19)*† 27 (8)
3 (2) 8 (10)*† 12 (3)
1 (1) 2 (3) 4 (1)
1 (1) 6 (8)*† 7 (2)
1 (1) 0 1 (1)
2 (1) 4 (5) 6 (2)
2 (1) 5 (7)*† 7 (2)
6 (4) 2 (3) 10 (3)
9 (6) 12 (16)*† 28 (8)
6 (4) 3 (4) 13 (4)
0 2 (3) 3 (1)
1 (1) 8 (11)*† 12 (3)
2 (1) 3 (4) 5 (1)
5 (4) 7 (9)* 13 (4)
nts with acute presentation.tery
Pr
oup 3,umb
, patierespectively).
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34). Two patients had hematuria, one of them also had
hemoptysis, and hematomas developed in the surgical
wounds of five patients. There was no stroke or death due
to thrombolysis.
Late results
Patency. Mean follow-upwas 4.2 years (range, 1month
to 20.7 years). Five-year primary and secondary patency rates
were 76% 3% and 87% 2%, respectively; they were higher
in GSV grafts (85% 3% and 94% 2%) than in PTFE grafts
(50%  7% and 63%  7%, P  .05; Fig 2). GSV grafts had
superior patency rates in all three groups. In group 3, second-
ary patency rates at 1 year were higher in patients with GSV
grafts than in those who had PTFE (96% 3% vs 67% 12%,
P  .001; Fig 3). In group 1, the 5-year secondary patency
rate ofGSVgraftswas 98%2% comparedwith 87%8% for
PTFE grafts (P .001).
In limbs with class II acute ischemia (threatened limb
Fig 2. Cumulative patency of 336 grafts after popliteal artery
aneurysm repair with great saphenous vein (GSV) or polytetrafluo-
roethylene (PTFE) grafts.
Fig 3. Cumulative patency of 72 grafts in group 3 (acute presen-
tation) after popliteal artery aneurysm repair with great saphenous
vein (GSV) or polytetrafluoroethylene (PTFE) grafts.ischemia),24 22 of 43 patients were available for follow-up.Preoperative thrombolysis appeared to improve primary
graft patency at 1 year (84% 9% vs 62% 12%, P .02).
Univariate analysis revealed multiple factors that were
more frequent in patients who developed graft occlusion
(Appendix, online only).28 Symptomatic patients, poor
runoff, distal anastomosis with pedal arteries, and PTFE
grafts were significant predictors for loss of primary patency
in a Cox proportional hazards model (Table V).
Reinterventions. To salvage a failing (n  21) or
failed (n 46) graft, 67 reinterventions were performed on
41 patients during follow-up. Reinterventions for recurrent
PAA were performed on seven (2%) of 358 limbs at a mean
of 35 months (range, 2 to 79months). Four had symptoms
of local compression, two had acute ischemia, and one had
chronic ischemia with rest pain. One of seven grafts was
occluded. All limbs had previous proximal and distal liga-
tion of the popliteal artery. The sac was opened through the
posterior approach in each patient, the hematoma was
evacuated, and feeding branches were ligated or oversewn.
One patient underwent repeat grafting with PTFE. The
5-year freedom from reintervention owing to PAA recur-
rence was 98%  1%, and 100% in those who underwent
endoaneurysmorrhaphy during the first operation vs 97%
2% in those with arterial ligation during revascularization of
the limb (P  .03).
Limb salvage. Overall limb loss was 3% (12/358) and
was 14% (10/74) in group 3. The 5-year cumulative limb
salvage rate was 97% 1%: 100% for group 1, 99% 1% for
group 2, and 85%  4% for group 3. Patients with GSV
grafts had better limb salvage at 5 years than those with
PTFE grafts (99% 1% vs 90% 3%, P .001). In group
3, the 5-year limb salvage with GSV graft was 93%  4% vs
66%  11% with PTFE grafts (P  .003; Fig 4). There was
no limb loss in group 1 and none in group 2 if GSV was
used for bypass. In group 3, preoperative thrombolysis in
26 lower limbs with class II acute ischemia (threatened
limb) appeared to reduce the amputation rate (96% 4% vs
69%  11%, P  .02).
Survival. Of the 107 patients who died during follow-
up, cardiac disease was the most frequent cause of death
Table V. Multivariate analysis of risk factors predicting
loss of primary patency
Variable HR (95% CI) P
Chronic symptoms 2.16 (1.20-3.88) .01
Acute presentation 2.57 (1.24-5.30) .01
Poor runoff * 2.44 (1.38-4.31) .002
Tibial bypass 1.66 (0.94-2.91) .08
Pedal bypass 5.44 (1.56-18.96) .008
PTFE 12.03 (6.47-22.36) .0001
GSV, nonreversed vs reversed 2.53 (1.28-5.00) .008
HR, Hazard ratio; CI, confidence interval; PTFE, polytetrafluoroethylene;
GSV, great saphenous vein.
*No tibial or peroneal artery visualized at the ankle level.(32%, 34/107). Five-year survival rate was 75%  3%.
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Aneurysm of the popliteal artery is a disease of men. It
is frequently bilateral and often associated with AAA. In a
review of the English literature that included 1673 patients
with PAAs,29 97% were men, a rate exactly the same as our
observation. Dawson et al29 found 50% had bilateral PAAs
and 36% had AAA. In our series, 54% of PAAs were bilateral
and 54% had AAA. We observed an increased prevalence of
AAAs in patients with bilateral (65%) vs unilateral (42%)
PAAs.
Thromboembolism is the most frequent complication
of PAAs; rupture is rare. Local compression increases the
risk for popliteal vein thrombosis, 6% of the patients in our
study had current or previous DVT. Duplex scan is excellent
for screening, to confirmmural thrombus, and for follow-up.
Contrast arteriography was frequently used in this retrospec-
tive study, but CT scan and three-dimensional CTA has
become the most important preprocedure imaging study. It
defines inflow and runoff and identifies concomitant aneu-
rysms elsewhere. In patients with renal insufficiency, MRA is
an excellent alternative.
Indications for interventions are well defined for pa-
tients who present with acute ischemia and for most of
those who have chronic ischemic symptoms. Patients with
severe claudication, rest pain, and tissue loss are considered
for elective repair, and patients who have symptoms of local
compression are also candidates for surgical repair.
Indications for asymptomatic patients and for those
with mild-to-moderate claudication are less well defined.
Factors affecting surgical decision include the rate of devel-
opment of symptoms, aneurysm size, mural thrombus,
evidence of previous thromboembolism, risk of surgical
repair, and long-term surgical outcome.
Michaels and Galland6 used Markov decision analysis
to determine optimum treatment of PAAs. To justify a
conservative approach, mortality and limb loss after repair
of symptomatic PAAs have to be close to those observed
Fig 4. Cumulative limb salvage of patients (group 3, acute pre-
sentations) after popliteal artery aneurysm repair with great saphe-
nous vein (GSV) or polytetrafluoroethylene (PTFE) grafts.after elective repair; alternatively, an asymptomatic patientgroup with an event rate of 10% per year has to be
identified.6 A review of 12 publications revealed that devel-
opment of symptoms averaged 14% per year (range, 5% to
24%).6 Lowell et al8 observed outcome in 67 patients with
PAAs initially managed conservatively, and symptoms de-
veloped in 18% during a mean follow-up of 17 months.
Factors predicting the development of symptoms included
size 2 cm, poor runoff, and mural thrombus (P  .05).8
Data to correlate aneurysm size with risk of thrombo-
embolism have been sparse. Whitehouse et al4 observed
that asymptomatic patients and those with claudication
have smaller aneurysms than those with acute ischemia or
local compressive symptoms. However, Ascher et al30
found that in a group of patients with 34 popliteal aneu-
rysms, those with smaller aneurysms developed more
thrombotic complications and a higher incidence of throm-
bosis and clinical symptoms than those with larger aneu-
rysms. Mural thrombus in small aneurysms ( 2 cm) was as
frequent (64%) as in large ones (70%).30
We found a correlation between aneurysm size and
clinical presentation: symptomatic patients presented with
larger aneurysms. Increasing size in addition to develop-
ment of symptoms were indications to intervene in 30% of
58 asymptomatic patients in one prospective multicenter
study.9 Galland et al31 found that the mean expansion rate
of PAAs was 1.5 mm/y for aneurysms20mm, 3.0 mm/y
for size 20 to 30 mm, and 3.7 mm/y for size 30 mm.
Distortion of the shape of the aneurysm in one study was
also more frequent in symptomatic patients.32
Mortality and complications after elective vs emergency
repair are major factors affecting the decision to treat
asymptomatic PAAs early. In a review of 13 surgical series,
Michaels and Galland6 found that asymptomatic patients
had 0.4% mortality and a 0.8% early rate of limb loss,
whereas symptomatic patients had 4.7% mortality and an
18.2% rate of early amputations.6 A sensitivity analysis
revealed that with a 1% elective mortality, it takes 34
months before surgical repair will be the preferred treat-
ment of asymptomatic patients. Fortunately, mortality for
repair in asymptomatic patients is 1% in most contempo-
rary surgical series,13,23,33 and we observed no elective
mortality and a low rate of complications. Several authors
advocate early repair of even small asymptomatic PAAs in
good-risk patients.3,4,6,34,35 High-risk patients with an in-
creased chance of surgical mortality (2% to 3%) are fre-
quently observed; those with suitable anatomy and high
risk for thromboembolic complications are now considered
for endovascular treatment.20-23
In patients with acute ischemia, we observed elevated
morbidity and mortality, and prolonged ICU and hospital
stays. An increased rate of complications in this group was
also reported by others,13,15,23,33 although one publication
on 51 patients, including 14 with emergency repair, re-
ported no early mortality or cardiac complications.14 Acute
ischemia in our series carried an 8% early risk and 15% late
risk of limb loss.
The GSV, implanted through a median approach, has
been our preferred graft. Advantages include easy harvest-
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optimal inflow and outflow. The proximal anastomosis was
the femoral artery in two thirds of the cases, and an infrapop-
liteal artery was used distally in one fourth of the operations.
The benefits of using the tibial arteries for the distal anasto-
mosis, if needed, were emphasized by Aulivola at al.14
Endoaneurysmorrhaphy should be performed for all
but the small, thrombosed aneurysms to prevent late recur-
rence.17 Depending on the location of the PAA, the sac is
approached either from below or from above the knee
incision by retracting the medial head of the gastrocnemius
muscle. A bloodless field can be assured using a thigh
tourniquet. The aneurysm is incised, and careful evacuation
of the thrombus is followed by oversewing the genicular
branches and suturing the posterior to the anterior wall.
Gelfoam or surgical fibrillar can be placed in the sac to aid
thrombosis. All reinterventions in this study were per-
formed in patients who underwent revascularization with
proximal and distal arterial ligation, without endoaneu-
rysmorrhaphy.
The posterior approach, used only in a small group of
our patients, was advocated by Beseth and Moore.16 This is
an effective approach to avoid recurrence of the aneurysm
because the sac is opened and all branches are ligated or
oversewn under direct vision. Interposition grafting is usually
done with a prosthetic graft, most frequently with PTFE.
Access to the distal superficial femoral artery or to the tibial
arteries through this approach is limited. In the experience of
Beseth and Moore, 13 patients required a medial approach
because of proximal (n11) or distal (n2) extension of the
disease; so 70% of the cases were suitable for posterior repair.
Pulli et al15 recently reported that 37% of 156 patients with
PAA were treated through a posterior approach and 61%
through a medial approach.
Selection of graft material has become somewhat con-
troversial because a prosthetic graft is a good size match to
the enlarged popliteal artery and a sizable number of pa-
tients with PAA have good-to-excellent runoff assuring
high flow and prolonged patency of a prosthesis. Pulli
et al15 found no difference in patency at 60 months be-
tween 118 PTFE grafts (71.5%) and 34 vein grafts (79.9%),
although the number of limbs at risk during this time
interval was not reported. Beseth and Moore16 implanted
25 PTFE and five Dacron grafts through the posterior
approach in patients with PAA, two with acute symptoms,
with a median follow-up of 21.5 months. Twenty-five
patients had two-vessel or three-vessel runoff. The 2-year
primary and secondary patencies were 92.2% and 95.8%,
with a limb salvage of 100%.
Although no controlled studies are available, most data
from the literature indicate superior long-term patency of
vein grafts vs prosthetic grafts. In a systemic review of
literature that included 2445 PAAs in 1673 patients, Daw-
son et al29 showed patency at 5 years of 77% to 100% for
vein grafts vs 29% to 74% for prosthetic grafts. The type of
conduit, the presence of symptoms, and the quality of the
runoff correlated with operative results. In our experience,
GSVs performed best: 5-year primary and secondary pa-tency rates were 85% and 94% for GSV, and 50% and 63%
for PTFE grafts. When GSV was used, no limb loss was
observed in patients who underwent elective repair for
asymptomatic PAA or for chronic ischemic symptoms.
To decrease the high rate of amputations, intra-arterial
thrombolysis has been used successfully in patients with
acute thromboembolism.9,18,19 Carpenter et al7 reported a
100% limb salvage rate for combined preoperative throm-
bolysis and bypass grafting compared with 57% for surgery
alone; however, the benefits of preoperative thrombolysis
have not always been confirmed by other investiga-
tors.10,11,13,15,36 In our experience, 1-year graft patency
and limb salvage rates appeared to improve with preopera-
tive thrombolysis. We continue to use thrombolysis in
patients who present with mild-to-moderate acute limb
ischemia (class I, IIa).
As with all retrospective studies, our review also has
certain limitations. Although general guidelines in manage-
ment as outlined in our report were followed, the selection
of graft material, surgical technique, and indications for
elective surgery were at the discretion of the vascular sur-
geon who performed the operation. There was no random-
ization to evaluate different techniques.
CONCLUSION
Our study confirmed that surgical treatment of acute
presentation of PAA continues to carry elevated mortality
and cardiac morbidity. Although preoperative thromboly-
sis appears to improve results, the 8% early and 15% late
amputation rates with acute presentation remains ominous.
Asymptomatic PAAs with thrombus or those with evidence
of distal embolization should be considered for repair.
PAAs 2 cm should be repaired even without mural
thrombus. Early elective repair is recommended to good-
risk patients with PAAs because operation in this group can
be performed with no surgical mortality, a low rate of
complications, and no limb loss for asymptomatic patients
at 5 years. In our experience GSV, and endoaneurysmor-
rhaphy continues to be the gold standard for open repair of
PAA.
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Dr Wesley Moore (Los Angeles, Calif). Dr Huang, Dr Glov-
iczki, I’d like to congratulate you for presenting probably the
largest series of popliteal artery aneurysms reported in the litera-
ture. I have a couple of questions concerning technique, and then
I’d like to make a comment regarding an alternative surgical
approach. It’s my understanding that rather than doing a simple
ligation and bypass, which is the usual technique for saphenous
vein reconstruction, you actually opened the aneurysm and tookDr Peter Gloviczki. That’s correct that many patients had
endoaneurysmorrhaphy, but still more patients had the proximal
and distal ligation. We have used both. Most recently we prefer to
use endoaneurysmorrhaphy.
Dr Moore. That very nicely addresses one of my major
concerns, which is the possibility of a type II endoleak that’s been
reported due to the continued patency of the branches of the
popliteal aneurysm that continue to fill and pressurize the aneu-
rysm in spite of ligation and bypass.
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of patients that we have treated with an alternative technique,
which is the posterior approach to popliteal aneurysm. The aneu-
rysm sac is opened, the geniculate branches are ligated fromwithin,
and a short interposition prosthetic graft is used for reconstruction.
This has the advantage of not needing to harvest the saphenous
vein. Thus we save the vein and avoid wound complications related
to vein harvest. Our 2-year patency is about 98%, and, therefore,
we believe that is more than competitive with ligation and vein
bypass. I’d be interested to know the average length of stay of your
patients and also what the wound complications were for the
saphenous vein harvest site.
Dr Gloviczki. I think the technique that Dr Moore described
obviously deserves a lot of attention because you don’t have to
exclude the aneurysm and you don’t have to do endoaneurysmor-
rhaphy. It’s very similar to the operation that we do in the abdom-
inal aorta when we do an in situ repair.
The problem that we have seen is that many of our patients
were not really suitable for a popliteal-popliteal repair. When we
looked at the type of repair that we used in our patients, of the 368
patients that we operated, we found only 90 patients who had a
popliteal-popliteal bypass. Now, that may be because our bias that
we use the median approach and it is sometimes easier to go above
Hunter’s canal than below Hunter’s canal. And also because we
have consistently found, during the years, that saphenous vein did
definitely better than a PTFE graft.
In the paper that you reported, 2-year results were excellent,
but over 80% of your patients had an excellent two- to three-vessel
runoff. Well, our PTFE graft patients did very well with three-
vessel runoff. In fact, our PTFE graft patency at 2 years was 100%
when our patients had a three-vessel runoff. So I think PTFE is an
excellent choice, and it is a good graft material if you have two- or
three-vessel runoff. But when you have patients who have one-
vessel runoff or you have no vessel that goes down to the foot, we
found that in every category, at every time, the durability of PTFE
grafts were less.
Coming back to the issue of complications and the possibility
to do endoaneurysmorrhaphy from the medial approach, we use a
tight tourniquet that permits us a relatively short incision in the sac
of the aneurysm from a medial approach, evacuate the thrombus
from the sac, and approximate the walls of the aneurysm with 3-0
polypropylene sutures.
Dr Moore. Do you want to comment on the wound compli-
cations?
Dr Gloviczki. We had 28 minor wound complications.
Dr Kevin Martin (Cincinnati, Ohio). You’re stating that
open repair with saphenous vein is still the gold standard for
popliteal aneurysms. Yet your name was associated in the lay press
with a high-profile person down in Washington with an endovas-
cular repair with PTFE, which you have just said doesn’t seem to
work as well. So I was wondering if you would enlighten us on
when youwould abandon the gold standard on high-profile people
and go with an alternative approach.
Dr Gloviczki. We certainly have not abandoned the gold
standard. We discussed all the options with the high-profile pa-
tient, and it is the patient’s choice to make a decision knowing the
fact of what type of procedure he or she would like to choose.
There is no question in my mind, and there was no question in my
recommendations, that saphenous vein is a more durable alterna-
tive. There is, however, clearly an issue with the low-risk patients
and high-risk patients, and there is clearly an elevated risk in those
patients who have multiple previous myocardial infarctions to
undergo a surgical procedure versus a stent graft. So I think the
selection by the patient, who by the way had exceptionally good
three-vessel runoff, has proven so far very appropriate, and I am
very hopeful that it’s going to also give him exceptionally good
long-term results.Dr Thomas Lindsay (Toronto, Ontario, Canada). Many
patients with popliteal aneurysms have very ectatic, dilated, super-
ficial femoral arteries also. You have alluded to that, I think when
you noted that 90 of your patients were appropriate for a short
distance bypass, which relates to DrMoore’s point. Can you tell us
howmany of these people have a dilated, multisegment aneurysmal
ectatic SFA that you felt you needed to be dealt with at the same
time as the popliteal aneurysm?
And secondly, what about the biology of these saphenous vein
grafts? Your study suggests that these venous grafts don’t get the
same intimal hyperplasia and we don;t have the same difficulties
with secondary patency issues as we seem to have in the atheroscle-
rotic patients. I wonder if you could give us any insights into that
biology.
Dr Gloviczki. You bring up a very good point, and we had
some discussion yesterday of who are anatomically suitable for
a popliteal-popliteal reconstruction or who are good candidates for
a Viabahn stent graft. When we looked carefully and analyzed a
group of 119 patients if they were suitable candidates for stent
grafts because of their anatomy, we found that the proximal
dilation or frank aneurysmal changes were quite frequently
present. So for instance, only 45% of the 119 patients that we
imaged would have been candidates for a stent graft. And one of
the main reason was exactly an aneurysmal or diffusely dilated
proximal artery.
Coming back to the issue of secondary changes of the grafts, it
is clear to me that aneurysmal disease is different from occlusive
disease. Saphenous veins do better and more important, PTFE
grafts do excellent, because of the high flow and good runoff. So
that is, clearly, one of the reasons why we don’t see so many
secondary changes in these grafts because aneurysmal patients
frequently have much better runoff than patients with occlusive
disease.
Dr Patrick Geraghty (St. Louis, Mo). I am envious of your
20-year data collection; it represents a significant effort. I think you
have conclusively proven the point that acute presentation results
in themajority of limb loss. As you know, we are presenting a small,
mid-term series of the popliteal aneurysm endograft repairs. I think
your data help to define a potential subset of candidates for
endovascular intervention, in the sense that when I look at your
patients who received a PTFE graft in an elective setting, they had
somewhat reduced patency rates but no increased rate of limb loss.
I think that from a patient’s perspective, it would be attractive if
you could be offered an endovascular approach initially, with a
fallback option of saphenous vein or PTFE bypass. That approach
may result in quicker recovery times without changing limb loss
rates.
Dr Gloviczki. I think you bring up a good point, that we
don’t exactly know who are those asymptomatic patients with
popliteal artery aneurysm who need the repair. We found that
thrombus burden in a large aneurysm is a predictor of potential
problems. And we are going to have a second paper where we are
going to analyze the amount of thrombus present in popliteal
aneurysm and the subsequent development of embolization or
chronic symptoms.
But clearly, size matters in the decision to on operate
asymptomatic patients, since we found a difference in the size of
aneurysm of the three groups when you don’t count those
patients who have thrombosed aneurysm. The larger the aneu-
rysm, the higher the chance of complications. Interestingly, the
size of the thrombosed aneurysm was not different between the
three groups. But the size of the aneurysm in asymptomatic
patients is significantly less than in chronic symptom patients
or in acute symptom patients. And I think the thrombus bur-
den will be another one of the predictors that we can use in
the future to guide us on recommending popliteal aneurysm
repair.
INVITED COMMENTARY
Thomas S. Huber, MD, PhD, Gainesville, Fla
The study by Gloviczki and colleagues documents their exten-
sive experience with the open surgical repair of popliteal artery
aneurysms. Despite the usual limitations of a single-center, retro-
spective study, it provides an exhaustive amount of information
and truly represents the gold standard for comparison with the
newer endovascular approaches. The study further confirms the
well-known male predominance, prevalence of associated aneu-
rysms, patterns of presentations, and favorable surgical outcomes
seen in patients with popliteal artery aneurysms. Several predictors
of graft failure were identified, including acute/chronic symptoms,
poor arterial runoff, distal anastomotic site, and conduit. Unfortu-
nately, the choice of conduit is usually the only factor among these
at the discretion of the surgeon. The authors’ excellent results
appear to validate their operative indications, particularly among
patients with asymptomatic aneurysms (operative indications,
asymptomatic [size 2 cm], presence of mural thrombus, or
evidence of thromboembolism). The authors conclude that endoa-
neurysmorrhaphy is superior to proximal/distal ligation on the
basis of an observed significant difference in the freedom-from-
reintervention rate (100% vs 98%; P  .03). Although I would
contend that the observed difference is likely not clinically signifi-
cant, their conclusion is likely correct given several recent publica-
tions documenting aneurysm growth (and compressive symptoms)
after ligation. Unfortunately, the data fail to clarify the role of
thrombolysis among patients presenting with acute lower extrem-
ity ischemia. However, they do suggest that thrombolysis may
confer an advantage in properly selected patients. The current
results strongly support the greater saphenous vein as the conduit
of choice but provide little guidance for the subset of patients in
whom it is inadequate. Finally, it is interesting to reflect on the
current results in light of the expanding list of publications docu-
menting the feasibility and safety of the alternative endovascular
approach. Interestingly, poor arterial runoff, a predictor of graft
failure in this study, was an exclusion criterion in the randomized,
controlled trial comparing open and endovascular popliteal artery
aneurysm repair cited previously (see reference 23). It is conceiv-
able that the endovascular approach may be equivalent to open
repair for asymptomatic patients with good arterial runoff, al-
though this needs to be confirmed by long-term follow-up.
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APPENDIX (online only). Univariate analysis of risk
factors predicting primary graft patency in 358 limbs with
popliteal artery aneurysm
n
5-year
patency HR P
High surgical risk* 358 .07
No 308 77.5 1.000
Yes 50 68.8 1.695
Groups 358 .003
Group 1 144 88.0 1.000
Group 2 140 71.5 2.087
Group 3 74 63.1 2.469
Number of runoff vessels 349 .001
0 57 48.8 3.031
1 147 77.3 1.320
2 127 83.3 0.682
3 18 93.3 1.000
Pedal arch 230 .003
Present or seen 83 86.1 1.000
Not present or not seen 147 62.5 3.482
Urgency of surgery 358 .001
Elective 325 79.6 1.000
Emergency 33 44.9 2.906
Surgical approach 358 .68
Posterior 21 76.9 1.000
Medial 337 76.3 1.206
Type of exclusion 344 .55
Endoaneurysmorrhaphy 115 79.3 1.000
Ligation 216 75.2 1.240
PAA thrombosis 358 .009
Patent 260 80.1 1.000
Completely thrombosed 98 66.1 1.760
Graft† 336 .001
GSV 242 85.4 1.000
PTFE 94 50.3 5.623
APPENDIX (online only). Univariate analysis of risk
factors predicting primary graft patency in 358 limbs with
popliteal artery aneurysm Continued.
n
5-year
patency HR P
GSV 242 .002
Reversed 149 91.9 1.000
Nonreversed 93 72.2 2.648
Proximal anastomosis 358 .001
Distal SFA 136 86.4 1.000
AK PA 102 81.9 1.121
Proximal and mid-SFA 36 67.5 2.324
Other 50 64.2 2.922
CFA 34 26.7 7.406
Distal anastomosis 358 .0001
BK popliteal bypass 268 78.0 1.000
Tibial bypass 86 74.3 1.455
Pedal bypass 4 — 8.082
Concomitant surgery 358 .02
No 225 80.9 1.000
Other aneurysm repair 59 68.7 1.806
Others interventions 74 65.5 1.839
HR, Hazard ratio; Group 1, asymptomatic; Group 2, patients with chronic
symptoms; Group 3, patients with acute presentation; GSV, great saphenous
vein; PTFE, polytetrafluoroethylene; SFA, superficial femoral artery; CFA,
common femoral artery; AK PA, above knee popliteal artery; BK, below
knee.
*Defined as age 80 years, myocardial infarction 6 months before sur-
gery, severe class IV angina or severe valvular heart disease, left ventricular
ejection fraction 30%, cardiac stress test positive for ischemia, severe
chronic obstructive or restrictive pulmonary disease (forced expiratory vol-
ume in 1 second 1.0), and serum creatinine 1.8 mg/dL.28
†Only GSV grafts and PTFE were compared, other autologous grafts and
Dacron grafts were excluded.
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